How to Buy Y Mabs Therapeutics Stock
Y Mabs Therapeutics Inc
Y-mAbs Therapeutics, Inc. , a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States.
Y Mabs Therapeutics stock last closed at $4.82, up 2.77% from the previous day, and has decreased 68.21% in one year. It has overperformed other stocks in the Biotechnology industry by 0.09 percentage points. Y Mabs Therapeutics stock is currently +24.87% from its 52-week low of $3.86, and -72.89% from its 52-week high of $17.78.
At the moment, there are 45.22M YMAB shares outstanding. The market capitalization of YMAB is $217.95M. In the past 24 hours, 143,300 YMAB shares were traded.
How to Buy Y Mabs Therapeutics Stock
Not sure how to invest in Y Mabs Therapeutics stock? Here's how.
- Figure out where to buy Y Mabs Therapeutics stock: You need to choose an online brokerage, but don't worry - we've analyzed dozens of online stock brokerages and apps to help you determine where to buy Y Mabs Therapeutics stock.
- Open your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Fund your brokerage account: Select your payment method and add your information.
- Research Y Mabs Therapeutics stock: The Y Mabs Therapeutics ticker symbol is YMAB. Is Y Mabs Therapeutics stock a good investment? Should you buy shares of YMAB? How do YMAB's underlying business fundamentals look? Do top analysts think Y Mabs Therapeutics is a good buy? Why has YMAB's stock price moved recently? (Hint: Our stock market analysis tools can help you figure out if YMAB is a good stock to buy).
- Make your YMAB buy order: Decide if you will purchase YMAB shares at the current market price or use a limit order to purchase YMAB stock at a particular price.
- Get updates on your YMAB investment: Create a watchlist to track your new investment in Y Mabs Therapeutics shares.
Step 1: Figure out where to buy Y Mabs Therapeutics stock
You need a brokerage account in order to access the NASDAQ market and buy YMAB stock.
Our preferred brokerage: eToro
Based on our experience, eToro is the best stock brokerage. eToro gives you:
- Invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
- Access to world financial markets: From Tech to Real Estate, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top exchanges.
- Social investing: eToro has a community with more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by creating an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Open your brokerage account
Now that you've chosen your brokerage, it's time to fill out some personal information so you are able to invest in YMAB stock today.
How to Create a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal details to start your new trading account.
- Send your application by hitting the "Create Account" button. Get started with eToro today
Step 3: Fund your brokerage account
Now that you've finished signing up on the stock trading app, you can securely and quickly fund your account:
Watch the walkthrough below if you need help depositing funds into your new investment account.
Step 4: Research Y Mabs Therapeutics stock
Once you have decided on the best place to buy Y Mabs Therapeutics stock, it's critical to evaluate their stock prior to investing, so you actually understand the risk and upside.
Y Mabs Therapeutics Metrics
Y Mabs Therapeutics Overview
WallStreetZen was designed to help everyday investors perform more accurate fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on YMAB's stock page.
What is the fair value of YMAB stock?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge YMAB's fair value.
Using relative valuations metrics:
- YMAB may be undervalued based on its P/B ratio of 2.37x, relative to Biotechnology industry P/B ratio of 4.04x
You can do more valuation analysis on YMAB's stock here.
YMAB Financial Health Overview
Pros:
- There are more short-term assets than short-term liabilities on the YMAB balance sheet.
- There are more short-term assets than long-term liabilities on the YMAB balance sheet.
- YMAB has $67.23M in cash and short term investments. This is enough to cover its annual cash burn of $15.71M.
- YMAB has cash burn of 15714000. It has enough cash and short-term investments to cover this for at least one year.
- YMAB has a low debt to equity ratio of 0.3.
Cons:
- Total YMAB debt is higher than 5 years ago, relative to shareholder equity.
- YMAB profit margin has gone down from -25.3% to -33.8% in the past year.
Do Wall Street analysts think it's a good time to buy Y Mabs Therapeutics stock
Out of 6 Equities analysts who give forecasts on YMAB, the consensus analyst rating on YMAB is a Buy
Please note that analyst ratings are not stock recommendations, nor are they financial advice.
Latest YMAB Analyst Forecasts
Jeff Jones, a bottom 13% analyst from Oppenheimer initiates coverage on YMAB with a buy rating and announces their YMAB price target of $23.00, on Nov 18, 2024.
You can dive deeper into what analysts are projecting on the Y Mabs Therapeutics stock forecast page.
YMAB Technical Indicators
YMAB Earnings
Last year, YMAB revenue was $87.69M. In the last four year, YMAB's revenue has increased by 43.38% per year. This was slower than the Biotechnology industry average of 44.31%.
Find out more about YMAB's earnings and revenue performance here.
Who is buying/selling YMAB?
In the past year, executives and large shareholders at YMAB have sold more shares than they have bought.
Thomas Gad, CHIEF BUSINESS OFFICER of YMAB, was the latest YMAB insider to sell. They sold $56,536.30 worth of YMAB stock on Mar 7, 2025.
Dig into more about who owns YMAB shares here.
Does YMAB provide a stable income stream?
No, Y Mabs Therapeutics doesn't provide an income stream by paying out dividends.
What others are saying about YMAB
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other community members have to say.
Step 5: Make your YMAB buy order
You have two main order types:
- Market order: A market order is an order to buy or sell a stock at the best price on the market.
Market orders are mostly sufficient. - Limit order: A limit order lets you buy or sell a stock at a specific price (or better).
If you want to be sure you're buying or selling at an exact dollar amount, use a limit order.
Click the Open Trade button and your broker will place your order.
If you need additional info about investing in stocks on eToro, watch the helpful video below:
Step 6: Get updates on your YMAB investment
Now that you own some YMAB shares, you'll want to keep up with your new company.
Start a watchlist to track the most important metrics related to your YMAB stock.
YMAB Feed
How to Buy Stock in Y Mabs Therapeutics
To reiterate, here are the 6 steps to buy Y Mabs Therapeutics stock:
- Figure out where to buy Y Mabs Therapeutics stock
- Open your brokerage account
- Fund your brokerage account
- Research Y Mabs Therapeutics stock
- Make your YMAB buy order
- Get updates on your YMAB investment
If you require a brokerage account, eToro is our favorite venue.
Get Started with eToro TodayIf you want to get the latest news on your investment in Y Mabs Therapeutics, create your watchlist below.
Trending "How To" Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.